Cargando…

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This was a multicentre, randomised, double-blind, placebo- an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bateman, Eric D., Ferguson, Gary T., Barnes, Neil, Gallagher, Nicola, Green, Yulia, Henley, Michelle, Banerji, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844137/ https://www.ncbi.nlm.nih.gov/pubmed/23722616 http://dx.doi.org/10.1183/09031936.00200212

Ejemplares similares

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
por: Zhong, Nanshan, et al.
Publicado: (2015)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
por: Dahl, Ronald, et al.
Publicado: (2013)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Dual Bronchodilator in the Era of Triple Therapy
por: Papaioannou, Andriana I, et al.
Publicado: (2020)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator
por: Ahmed, Mona Ibrahim, et al.
Publicado: (2023)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Spirometry and Bronchodilator Test
por: Sim, Yun Su, et al.
Publicado: (2017)

Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline
por: Jeong, Ho Jung, et al.
Publicado: (2016)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Publicado: (2014)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Cardiovascular morbidity and the use of inhaled bronchodilators
por: Macie, Christine, et al.
Publicado: (2008)

Do bronchodilators have an effect on bronchiolitis?
por: Schindler, Margrid
Publicado: (2002)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

Bronchodilator responsiveness and dysanapsis in bronchopulmonary dysplasia
por: Nelin, Leif D., et al.
Publicado: (2022)

Patterns of bronchodilator therapy in asthmatic outpatients
por: Aryani, Toetik, et al.
Publicado: (2023)

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
por: Vogelmeier, Claus F., et al.
Publicado: (2020)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
por: Price, David, et al.
Publicado: (2016)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of inhaled and/or nasal corticosteroids on the bronchodilator response
por: Lee, Ju Kyung, et al.
Publicado: (2010)

Assessment of Bronchodilator Response in Various Spirometric Patterns
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2013)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Spirometry and bronchodilator responsiveness in wheezing preschool children
por: Leiria-Pinto, Paula, et al.
Publicado: (2015)

Inhaled Bronchodilator Use for Infants with Bronchopulmonary Dysplasia
por: Slaughter, Jonathan L, et al.
Publicado: (2014)

Latrophilin receptors: novel bronchodilator targets in asthma
por: Faiz, A, et al.
Publicado: (2017)

A Novel in vivo System to Test Bronchodilators
por: Addison, Kenneth J, et al.
Publicado: (2017)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1va6bfdvu7oljjr4f0sa6902bb